Alison G Abraham1, Keri N Althoff1, Yuezhou Jing1, Michelle M Estrella2, Mari M Kitahata3, C William Wester4, Ronald J Bosch5, Heidi Crane3, Joseph Eron6, M John Gill7, Michael A Horberg8, Amy C Justice9, Marina Klein10, Angel M Mayor11, Richard D Moore12, Frank J Palella13, Chirag R Parikh14, Michael J Silverberg15, Elizabeth T Golub1, Lisa P Jacobson1, Sonia Napravnik6, Gregory M Lucas2. 1. Johns Hopkins Bloomberg School of Public Health. 2. Johns Hopkins School of Medicine, Baltimore, Maryland. 3. University of Washington, Seattle. 4. Vanderbilt University School of Medicine, Nashville, Tennessee. 5. Harvard School of Public Health, Boston, Massachusetts. 6. University of North Carolina, Chapel Hill. 7. University of Calgary, Alberta, Canada. 8. Mid-Atlantic Kaiser Permanente Research Institute, Rockville, Maryland. 9. Veterans Affairs Healthcare System, West Haven, Connecticut Yale University, New Haven, Connecticut; 10. McGill University, Montreal, Quebec, Canada. 11. Universidad Central del Caribe, Bayamon, Puerto Rico. 12. Johns Hopkins Bloomberg School of Public Health Johns Hopkins School of Medicine, Baltimore, Maryland. 13. Northwestern University, Chicago, Illinois. 14. Yale University, New Haven, Connecticut; 15. Kaiser Permanente Northern California, Oakland.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-infected adults, particularly those of black race, are at high-risk for end-stage renal disease (ESRD), but contributing factors are evolving. We hypothesized that improvements in HIV treatment have led to declines in risk of ESRD, particularly among HIV-infected blacks. METHODS: Using data from the North American AIDS Cohort Collaboration for Research and Design from January 2000 to December 2009, we validated 286 incident ESRD cases using abstracted medical evidence of dialysis (lasting >6 months) or renal transplant. A total of 38 354 HIV-infected adults aged 18-80 years contributed 159 825 person-years (PYs). Age- and sex-standardized incidence ratios (SIRs) were estimated by race. Poisson regression was used to identify predictors of ESRD. RESULTS: HIV-infected ESRD cases were more likely to be of black race, have diabetes mellitus or hypertension, inject drugs, and/or have a prior AIDS-defining illness. The overall SIR was 3.2 (95% confidence interval [CI], 2.8-3.6) but was significantly higher among black patients (4.5 [95% CI, 3.9-5.2]). ESRD incidence declined from 532 to 303 per 100 000 PYs and 138 to 34 per 100 000 PYs over the time period for blacks and nonblacks, respectively, coincident with notable increases in both the prevalence of viral suppression and the prevalence of ESRD risk factors including diabetes mellitus, hypertension, and hepatitis C virus coinfection. CONCLUSIONS: The risk of ESRD remains high among HIV-infected individuals in care but is declining with improvements in virologic suppression. HIV-infected black persons continue to comprise the majority of cases, as a result of higher viral loads, comorbidities, and genetic susceptibility.
BACKGROUND: Human immunodeficiency virus (HIV)-infected adults, particularly those of black race, are at high-risk for end-stage renal disease (ESRD), but contributing factors are evolving. We hypothesized that improvements in HIV treatment have led to declines in risk of ESRD, particularly among HIV-infected blacks. METHODS: Using data from the North American AIDS Cohort Collaboration for Research and Design from January 2000 to December 2009, we validated 286 incident ESRD cases using abstracted medical evidence of dialysis (lasting >6 months) or renal transplant. A total of 38 354 HIV-infected adults aged 18-80 years contributed 159 825 person-years (PYs). Age- and sex-standardized incidence ratios (SIRs) were estimated by race. Poisson regression was used to identify predictors of ESRD. RESULTS:HIV-infected ESRD cases were more likely to be of black race, have diabetes mellitus or hypertension, inject drugs, and/or have a prior AIDS-defining illness. The overall SIR was 3.2 (95% confidence interval [CI], 2.8-3.6) but was significantly higher among black patients (4.5 [95% CI, 3.9-5.2]). ESRD incidence declined from 532 to 303 per 100 000 PYs and 138 to 34 per 100 000 PYs over the time period for blacks and nonblacks, respectively, coincident with notable increases in both the prevalence of viral suppression and the prevalence of ESRD risk factors including diabetes mellitus, hypertension, and hepatitis C virus coinfection. CONCLUSIONS: The risk of ESRD remains high among HIV-infected individuals in care but is declining with improvements in virologic suppression. HIV-infected black persons continue to comprise the majority of cases, as a result of higher viral loads, comorbidities, and genetic susceptibility.
Authors: Mohamed G Atta; Derek M Fine; Gregory D Kirk; Shruti H Mehta; Richard D Moore; Gregory M Lucas Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079
Authors: K C Norris; M Thornhill-Joynes; C Robinson; T Strickland; B L Alperson; S C Witana; H J Ward Journal: Am J Kidney Dis Date: 2001-09 Impact factor: 8.860
Authors: Lynda Anne Szczech; Samir K Gupta; Ramez Habash; Antonio Guasch; Robert Kalayjian; Richard Appel; Timothy A Fields; Laura P Svetkey; Katherine H Flanagan; Paul E Klotman; Jonathan A Winston Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Lesley A Inker; Christina Wyatt; Rebecca Creamer; James Hellinger; Matthew Hotta; Maia Leppo; Andrew S Levey; Aghogho Okparavero; Hiba Graham; Karen Savage; Christopher H Schmid; Hocine Tighiouart; Fran Wallach; Zipporah Krishnasami Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: L Ryom; O Kirk; J D Lundgren; P Reiss; C Pedersen; S De Wit; S Buzunova; J Gasiorowski; J M Gatell; A Mocroft Journal: HIV Med Date: 2013-04-16 Impact factor: 3.180
Authors: Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: Jordana B Cohen; Jayme E Locke; Brittany Shelton; Rhiannon D Reed; Margaux Mustian; Paul MacLennan; Kimberly A Forde; Peter P Reese; Deirdre Sawinski Journal: Clin Transplant Date: 2019-01-12 Impact factor: 2.863
Authors: Adrienne Tin; Long Zhang; Michelle M Estrella; Andy Hoofnagle; Casey M Rebholz; Todd T Brown; Frank J Palella; Mallory D Witt; Lisa P Jacobson; Lawrence A Kingsley; Alison G Abraham Journal: AIDS Res Hum Retroviruses Date: 2017-09-05 Impact factor: 2.205
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612
Authors: Sarah E Van Pilsum Rasmussen; Macey L Henderson; Juli Bollinger; Shanti Seaman; Diane Brown; Christine M Durand; Dorry L Segev; Jeremy Sugarman Journal: AIDS Care Date: 2018-05-03
Authors: J F Suarez; R Rosa; M A Lorio; M I Morris; L M Abbo; J Simkins; G Guerra; D Roth; W L Kupin; A Mattiazzi; G Ciancio; L J Chen; G W Burke; M J Goldstein; P Ruiz; J F Camargo Journal: Am J Transplant Date: 2016-04-04 Impact factor: 8.086